252 related articles for article (PubMed ID: 18049473)
1. The way forward in HCV treatment--finding the right path.
Manns MP; Foster GR; Rockstroh JK; Zeuzem S; Zoulim F; Houghton M
Nat Rev Drug Discov; 2007 Dec; 6(12):991-1000. PubMed ID: 18049473
[TBL] [Abstract][Full Text] [Related]
2. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
3. Treatment and vaccination for hepatitis C: present and future.
Jawaid A; Khuwaja AK
J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
[TBL] [Abstract][Full Text] [Related]
4. Molecular biology of hepatitis C infection.
Drazan KE
Liver Transpl; 2000 Jul; 6(4):396-406. PubMed ID: 10915159
[TBL] [Abstract][Full Text] [Related]
5. [Molecular mechanisms of the hepatitis C virus, potential therapeutic targets].
Rivas-Estilla AM; Panduro A
Rev Invest Clin; 2003; 55(1):51-64. PubMed ID: 12708164
[TBL] [Abstract][Full Text] [Related]
6. Experimental models for hepatitis C viral infection.
Boonstra A; van der Laan LJ; Vanwolleghem T; Janssen HL
Hepatology; 2009 Nov; 50(5):1646-55. PubMed ID: 19670425
[TBL] [Abstract][Full Text] [Related]
7. HCV research and anti-HCV drug discovery: toward the next generation.
Wakita T
Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus virology and new treatment targets.
Meier V; Ramadori G
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
[TBL] [Abstract][Full Text] [Related]
9. HIV and hepatitis C coinfection.
Matthews GV; Dore GJ
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
[TBL] [Abstract][Full Text] [Related]
10. A primer on the molecular virology of hepatitis C.
Moradpour D; Blum HE
Liver Int; 2004 Dec; 24(6):519-25. PubMed ID: 15566499
[TBL] [Abstract][Full Text] [Related]
11. Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches.
von Hahn T; Steinmann E; Ciesek S; Pietschmann T
Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):63-79. PubMed ID: 20136590
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B and hepatitis C in 2009.
Marcellin P
Liver Int; 2009 Jan; 29 Suppl 1():1-8. PubMed ID: 19207959
[TBL] [Abstract][Full Text] [Related]
13. Towards a better understanding of HCV transmission and course of infection.
Berger A; Doerr HW
Infection; 2004 Jun; 32(3):125. PubMed ID: 15188069
[No Abstract] [Full Text] [Related]
14. Glucosidase inhibitors as antiviral agents for hepatitis B and C.
Durantel D; Alotte C; Zoulim F
Curr Opin Investig Drugs; 2007 Feb; 8(2):125-9. PubMed ID: 17328228
[TBL] [Abstract][Full Text] [Related]
15. HCV-associated lymphomas.
Fiorilli M; Mecucci C; Farci P; Casato M
Rev Clin Exp Hematol; 2003 Dec; 7(4):406-23. PubMed ID: 15129650
[TBL] [Abstract][Full Text] [Related]
16. The design of drugs for HIV and HCV.
De Clercq E
Nat Rev Drug Discov; 2007 Dec; 6(12):1001-18. PubMed ID: 18049474
[TBL] [Abstract][Full Text] [Related]
17. Development of novel treatments for hepatitis C.
Webster DP; Klenerman P; Collier J; Jeffery KJ
Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
[TBL] [Abstract][Full Text] [Related]
18. Resistance mechanisms in HCV: from evolution to intervention.
Kim AY; Timm J
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):463-78. PubMed ID: 18662114
[TBL] [Abstract][Full Text] [Related]
19. Non-human primate surrogate model of hepatitis C virus infection.
Akari H; Iwasaki Y; Yoshida T; Iijima S
Microbiol Immunol; 2009 Jan; 53(1):53-7. PubMed ID: 19161559
[TBL] [Abstract][Full Text] [Related]
20. Boceprevir, an NS3 protease inhibitor of HCV.
Berman K; Kwo PY
Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
